First Oral Drug for Secondary Progressive MS Tops SPT Week in Review


Top news of the week from Specialty Pharmacy Times.

5. Study Supports Comparable Efficacy of Generic and Brand-Name Drugs for Chronic Conditions

The findings could help promote interventions aimed at improving patient and provider confidence in generic drugs for managing chronic diseases. Read more.

4. Long-standing Drug Treatment May Prolong Life for MS Patients

Study is the first and largest of its kind to examine mortality associated with beta interferons, the first drugs to be approved for the treatment of relapsing-onset multiple sclerosis. Read more.

3. Combined Immunosuppression Effective for Older Patients with Crohn Disease

Study finds older patients administered combined immunosuppression experienced similar remission of Crohn disease as those aged under 60 years. Read more.

2. FDA Approves First Treatment for Non-Radiographic Axial Spondyloarthritis

Certolizumab pegol (Cimzia) is the first FDA-approved therapy for this type of axial spondyloarthritis, filling an unmet clinical need for treatment options. Read more.

1. FDA OKs Siponimod, First Oral Drug for Active Secondary Progressive MS

Novartis’ siponimod (Mayzent) is approved for adults with active secondary progressive multiple sclerosis, clinically isolated syndrome, and relapsing-remitting disease. Read more.

Related Videos
Credit: Adobe Stock - Tierney
Yaruniv-Studio -
Technician- © pharmacytimes
Pills on a background of a one hundred American dollar bill | Image credit: Cagkan -
Credit: Cagkan -
Specialty pharmacy illustration | Image credit: -
Related Content
© 2023 MJH Life Sciences

All rights reserved.